What question did this study set out to answer?

The aim is to explore how RAD51 transitions from a factor of vulnerability to one of resistance in breast cancer treatment.

RAD51 in Breast Cancer: From Vulnerability to Resistance

View Full Paper

Ask AI

Bookmark

Authors

Review explains RAD51's role in breast cancer, showing how it transitions from sensitivity to resistance.

The aim is to explore how RAD51 transitions from a factor of vulnerability to one of resistance in breast cancer treatment.
Review of existing literature on RAD51's role in homologous recombination and replication fork dynamics.
Analysis of functional biomarkers and subtype-specific dependencies of RAD51 in breast cancer.
Discussion on therapeutic strategies for targeting RAD51 in resistant tumors.
RAD51 deficiency leads to heightened sensitivity to DNA-damaging agents in BRCA1 and BRCA2 mutant tumors.
Restoration of RAD51 function contributes to resistance against PARP inhibitors despite existing genomic scars.
Identifying the dynamic role of RAD51 in replication fork protection can enhance precision oncology approaches.

Anjum et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark